Study shows tofacitinib medication can fix porousness absconds in the digestive tract Kumar Jeetendra | October 6, 2020 A team of researchers led by biomedical scientist Declan F. McCole in the University of California, Riverside, has found that the medication tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can fix permeability defects in the intestine. Study results appear in the Journal of Crohn’s and Colitis. …
Study offers understanding into metabolic pathways hijacked by SARS-CoV-2 for viral replication Kumar Jeetendra | March 16, 2021 When SARS-CoV-2, the virus which causes COVID-19, infects a human cell, it quickly begins to replicate by seizing the cell’s existing metabolic machinery. The infected cells churn out thousands of viral genomes and proteins while halting the creation of their own sources. Researchers from Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), and the Broad …
Genetic variants that sway protein restricting in immune cells can cause autoimmune disease Kumar Jeetendra | April 17, 2021 Certain genetic variants that cause modified protein binding in immune cells, are also seen in people at high risk of some autoimmune diseases, new research has found. Researchers from the Wellcome Sanger Institute, Josep Carreras Leukaemia Research Institute in Spain, and the MRC London Institute of Medical Sciences (LMS) discovered that specific genetic variants, which …
